Clinical and structural brain correlates of hypomimia in early-stage Parkinson's disease

Frederic Sampedro¹,²,³ | Saul Martínez-Horta¹,²,³ | Andrea Horta-Barba¹,²,³ | Michel J. Grothe¹,⁴ | Miguel A. Labrador-Espinosa¹,⁴ | Silvia Jesús¹,⁴ | Astrid Adames-Gomez¹,⁴ | Fatima Carrillo⁵ | Arnau Puig-Davi¹,²,³ | Florinda Roldan-Lora⁶ | Miquel Aguilar-Barbera⁷ | Pau Pastor⁷ | Sonia Escalante Arroyo⁸ | Berta Solano Vila⁹ | Anna Cots-Foraster⁹ | Javier Ruiz-Martínez¹⁰ | Francisco Carrillo-Padilla¹¹ | Mercedes Pueyo-Morlan² | Isabel Gonzalez-Aramburu¹² | Jon Infante-Ceberio¹² | Jorge Hernandez-Vara¹³ | Oriol de Fabregues-Boixar¹³ | Teresa de Deus Fonticoba¹⁴ | Asucon Avila¹⁵ | Juan Carlos Martínez-Castrillo¹⁶ | Helena Bejr-Kasem¹,²,³ | Antonia Campolongo¹,²,³ | Berta Pascual-Sedano¹,²,³ | Pablo Martínez-Martín¹ | Diego Santos-García¹⁷ | Pablo Mir¹,⁴ | COPPADIS Study Group | Pedro J. Garcia-Ruiz¹⁸ | Jaime Kulisevsky¹,²,³

¹Centro de Investigacion Biomedica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
²Unidad de Trastornos del Movimiento, Servicio de Neurología, Hospital de Sant Pau, Barcelona, Spain
³Instituto de Investigacion del Hospital de Sant Pau, Barcelona, Spain
⁴Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
⁵Movement Disorders Unit, Neurology Department, Hospital Universitario Virgen del Rocío, Seville, Spain
⁶Unidad de Radiodiagnostico, Hospital Universitario Virgen del Rocío, Seville, Spain
⁷Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain
⁸Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Tarragona, Spain
⁹Institut Catala de la Salud (Girona), Institut d’Assistencia Sanitaria (IAS), Girona, Spain
¹⁰Instituto de Investigacion Biodonostia, Hospital Universitario Donostia, San Sebastian, Spain
¹¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
¹²Unidad de Trastornos del Movimiento, Servicio de Neurología, Hospital Universitario Marques de Valdecilla, Santander, Spain
¹³Neurology Department and Neurodegenerative Diseases Research Group, Vall d’Hebron University Campus, Barcelona, Spain
¹⁴Complejo Hospitalario Universitario de Ferrol (CHUF), Hospital Arquitecto Marcide, Ferrol, Spain
¹⁵Consorci Sanitari Integral, Hospital General de L’Hospitalet, L’Hospitalet de Llobregat, Barcelona, Spain
¹⁶Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain
¹⁷Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain
¹⁸Department of Neurology, Fundación Jimenez Diaz, Madrid, Spain

Frederic Sampedro and Saul Martínez-Horta contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
INTRODUCTION

Hypomimia, a reduced degree of facial expression for spontaneous and emotional movements, is a classical and very frequent symptom of Parkinson’s disease (PD) [1, 2]. Lack of or reduced facial expression of emotions has a substantial impact on patients, partners and caregivers. For all of them, hypomimia arises as a stigma that significantly impacts quality of life [3], social wellbeing and interpersonal relationships, and that gradually increases social isolation [2, 4, 5].

Hypomimia is typically considered to be a form of bradykinesia of the facial muscles and to be primarily mediated by motor basal ganglia dysfunction [4]. Accordingly, hypomimia is rated as a motor sign for which its gradation is associated with the severity of the disease [6, 7]. Therefore, hypomimia can improve with dopamine-replacement treatment, an effect possibly mirroring the changes observed in axial motor symptoms induced by treatment with levodopa [8]. However, the evolutionary particularities of human facial expression and the multiplicity of functions of facial muscles, compared to limb muscles, make facial muscle innervation and control unique [9, 10]. The mechanisms involved in involuntary and voluntary facial expression of emotions are not comparable to other systems of motor control. Moreover, in contrast to limb bradykinesia, it has been suggested that hypomimia is not usually asymmetrical, although some studies found that the most expressive face side is usually the less affected body side in terms of bradykinesia [6, 11, 12].

Thus, the question arises as to whether hypomimia is a pure motor disorder [11, 13] or if, in contrast, this symptom is a consequence of a more complex set of defective neural, cognitive and affective mechanisms. Preliminary evidence supporting hypomimia as a non-motor symptom of PD comes from studies associating hypomimia to impairment in facial emotion recognition [14, 15]. Facial emotion recognition deficits are more pronounced in PD patients with apathy [16] and in PD patients with cognitive impairment [17]. Moreover, in PD there is also an association between impairment in posing facial expressions of emotions and deficits in facial emotion recognition [13]. A recent study showed that patients with hypomimia had more severe apathy and axial signs than patients without hypomimia, but that they did not differ in terms of depression, anxiety and neuropsychological performance [8].
Less is known about the association between hypomimia and cognition in PD. One recent study in a relatively small sample of patients observed that the severity of hypomimia was positively correlated with axial symptoms and negatively correlated with cognitive performance [11]. Similar results indicating that more severe hypomimia was associated with worse cognitive scores independently of motor severity were obtained using a larger sample of untreated PD patients from the Parkinson’s Progression Markers Initiative [18].

In the present study, associations between hypomimia, motor symptoms, apathy and cognition in a large observational cohort study of already treated non-demented PD patients were examined, and the neural correlates of the severity of hypomimia as assessed by multimodal magnetic resonance imaging (MRI) acquisitions were further assessed.

**MATERIALS AND METHODS**

**Sample and assessments**

Cross-sectional data from the Cohort of Patients with Parkinson’s Disease in Spain (COPPADIS) study (database released in May 2019) were used [19]. Details regarding the methods used in the COPPADIS study can be found in the original publications [19]. A total of 506 PD participants were included for whom the following variables were available: age, disease duration, levodopa equivalent daily dose (LEDD), the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) [7], the apathy item of the Neuropsychiatric Inventory (NPI) [20], Beck’s Depression Inventory [21] and the Parkinson’s Disease—Cognitive Rating Scale (PD-CRS) [22].

The severity of hypomimia was rated through the UPDRS-III facial expression item which grades eye-blink frequency, masked facies or loss of facial expression, spontaneous smiling, and parting of lips from 0, normal, to 1, slight; 2, mild; 3, moderate; and 4, severe. Global motor status was rated with all the components of the UPDRS-III. To further explore the association between hypomimia and other clinical and imaging parameters controlling the effect of other motor symptoms, a secondary motor score derived from the total Movement Disorder Society UPDRS-III score minus the facial expression score was also computed. The bradykinesia subscore of the UPDRS was also computed (sum of items 2, 4–9 and 14) [23].

The severity of apathetic symptoms and the severity of depressive symptoms were respectively rated with the apathy item of the NPI and Beck’s Depression Inventory. Global cognitive status was rated with the PD-CRS. Cut-off scores for mild cognitive impairment (PD-MCI) and for dementia (PDD) were used to identify participants with normal cognition, PD-MCI or PDD [22, 24]. The frontal-subcortical and posterior-cortical PD-CRS summary scores and the scores from performance in each PD-CRS subtest were also collected.

**Statistical analyses**

First, simple correlational analyses were performed to explore the association between hypomimia and age, disease duration, LEDD, UPDRS-III scores, depressive symptoms, apathy and cognitive performance. To more deeply address the association between hypomimia and all the other UPDRS-III items, a univariate regression analysis was first performed between the facial expression item and the total UPDRS-III score minus facial expression, using disease duration and LEDD as covariates. In a second step, to better disentangle the specific items of the UPDRS-III associated with hypomimia, the data were subjected to a second univariate regression analysis including all the UPDRS-III items as fixed factors and using disease duration, age and LEDD as covariates.

To explore the association between hypomimia and other clinical variables, separate univariate regression analyses were conducted between hypomimia and depression, apathy and cognitive status, using as covariates all the UPDRS-III items minus those that appeared to be indissociable from hypomimia in the previous analysis. Finally, a binary logistic regression analysis was performed with participants classified as with and without clinically relevant apathetic symptoms (NPI apathy ≥2) [25] and hypomimia, age, disease duration, LEDD and UPDRS-III items minus those involved in hypomimia as predictors. Given that previous studies have supported that asymmetry of facial expression occurs in PD and is related to asymmetry of motor impairment [12, 13], the analyses were repeated after controlling for motor laterality. For these analyses, the SPSS statistical package was used, and $p < 0.05$ was considered significant.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

**Neuroimaging add-on study**

A subset of 132 patients had T1-MRI available. These data were used to explore the structural neuroimaging correlates of facial expression in PD. Details about the image acquisition protocols in the COPPADIS cohort have been reported previously [19].

Regarding neuroimaging preprocessing, two procedures were applied to quantify gray matter integrity. On the one hand, to assess cortical atrophy, a standard surface-based cortical thickness (Cth) pipeline using FreeSurfer 6.0 was used to obtain vertexwise Cth data for each patient. These Cth maps were normalized to a standard fsaverage space and smoothed using a Gaussian kernel of 15 mm full-width at half-maximum (FWHM).

On the other hand, subcortical differences in gray matter volume (GMV) were assessed by a standard GMV voxel-based morphometry pipeline using the SPM12 toolbox. Briefly, voxelwise GMV maps were obtained by probabilistic tissue-based segmentation normalized to the standard MNI space and smoothed using an isotropic kernel of 8 mm FWHM. This voxel-based morphometry analysis was restricted to subcortical regions.
Neuroimaging regression analyses were performed to study the GMV and Cth correlates of facial expression, using age as a nuisance covariate. To do this, a global map was first obtained from the regression using the UPDRS-III total score. For the latter neuroimaging analyses, only the set of clusters surviving \( p < 0.05 \) and multiple comparison correction (Monte Carlo with 10,000 repeats for Cth and small-volume random field theory for GMV) were considered significant.

The sets of GMV and Cth maps obtained were then used to explore the specific association between hypomimia and distinct clusters of GMV and Cth. Thus, to delimit those clusters in association with hypomimia without the collinear contribution of the other UPDRS-III items, LEDD or disease duration, a univariate regression analysis was conducted using hypomimia and related UPDRS-III items as dependent variables and all the other UPDRS-III scores, age, disease duration and LEDD as covariates.

**RESULTS**

The sample was composed of 506 PD participants from the COPPADIS study with mean age 62.3 ± 9.1 years, mean disease duration 5.5 ± 4.3 years and mean UPDRS-III = 23.4 ± 11.4. Table 1 shows the sociodemographic and clinical characteristics of the sample. Bradykinesia was found to be more severe on the left side (t(506) = −2.6; \( p = 0.008 \)). In the sample, according to the PD-CRS total score, 71.1% (\( n = 360 \)) were cognitively preserved, 22.1% (\( n = 112 \)) were classified as PD-MCI and 6.7% (\( n = 34 \)) were classified as PDD.

<table>
<thead>
<tr>
<th>TABLE 1</th>
<th>Clinical and sociodemographic characteristics of the sample</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean (SD)</strong></td>
<td><strong>Range</strong></td>
</tr>
<tr>
<td>Age (years)</td>
<td>62.2 (9.1)</td>
</tr>
<tr>
<td>Disease duration</td>
<td>5.5 (4.3)</td>
</tr>
<tr>
<td>UPDRS-III total</td>
<td>23.4 (11.4)</td>
</tr>
<tr>
<td>Hypomimia</td>
<td>1.2 (0.7)</td>
</tr>
<tr>
<td>Bradykinesia</td>
<td>8.9 (5.1)</td>
</tr>
<tr>
<td>Left side</td>
<td>4.6 (3.2)</td>
</tr>
<tr>
<td>Right side</td>
<td>4.2 (2.9)</td>
</tr>
<tr>
<td>LEDD</td>
<td>576.4 (418.5)</td>
</tr>
<tr>
<td>BDI-II</td>
<td>9.5 (7.3)</td>
</tr>
<tr>
<td>NPI—Apathy</td>
<td>1.3 (2.3)</td>
</tr>
<tr>
<td>PD-CRS total</td>
<td>91.1 (16.3)</td>
</tr>
<tr>
<td>Frontal-subcortical</td>
<td>63.6 (14.8)</td>
</tr>
<tr>
<td>Posterior-cortical</td>
<td>27.4 (3.4)</td>
</tr>
</tbody>
</table>

Abbreviations: BDI-II, Beck’s Depression Inventory; LEDD, levodopa equivalent daily dose; NPI, Neuropsychiatric Inventory; PD-CRS, Parkinson’s Disease—Cognitive Rating Scale; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III.

In a simple correlational analysis, the direct association between hypomimia and age, disease duration, LEDD, UPDRS-III scores, depressive symptoms, apathy and cognitive performance was explored. As expected, associations were found between hypomimia and disease duration (\( r = 0.167; p < 0.0002 \), LEDD (\( r = 0.223; p < 0.0001 \)) and UPDRS-III (hypomimia item excluded) (\( r = 0.516; p < 0.0001 \)). Significant associations were also found between hypomimia and severity of depressive symptoms (\( r = 0.139; p = 0.002 \)), apathy (\( r = 0.169; p < 0.0001 \)) and cognitive status as measured with the PD-CRS total score (\( r = −0.233; p < 0.0001 \)).

Focusing on the exploration of the association between hypomimia and other motor symptoms, a univariate regression analysis was performed using disease duration and LEDD as covariates. This first step showed a moderate association between hypomimia and UPDRS-III minus hypomimia score (\( r^2 = 0.349; F_{(1.53)} = 3.83; p < 0.0001 \)).

In a second step, to better disentangle the specific items of the UPDRS-III associated with hypomimia, the data were subjected to a second univariate regression analysis including all the UPDRS-III items as fixed factors and using disease duration, age and LEDD as covariates. This analysis showed that the main UPDRS-III items associated with hypomimia were speech (\( F_{(1.53)} = 20.05; p < 0.0001 \)) and bradykinesia-hypokinesia (\( F_{(1.53)} = 4.01; p = 0.003 \)). Thus, these two factors (speech and bradykinesia-hypokinesia) were assumed not as confounders but as inherent to hypomimia.

Thirdly, the association between hypomimia and other clinical symptoms that appeared as directly correlated in the simple correlational analysis was explored. A separate univariate regression analysis was conducted between hypomimia and depression, apathy and cognitive status, using as covariates all the UPDRS-III items as fixed factors and using disease duration, age and LEDD as covariates. This analysis showed an absence of association between depression, cognitive status and hypomimia, but a significant, albeit relatively low, association between hypomimia and apathy severity (\( r = 0.595; p < 0.0001 \)). Following this finding, a binary logistic regression analysis was performed with participants classified as presenting with and without clinically relevant apathetic symptoms (NPI apathy severity ≥2) and hypomimia, age, disease duration and LEDD. This analysis showed a strong association between hypomimia and clinically relevant apathy (\( \beta = 0.595; p < 0.0001 \)). These associations remained significant after controlling for motor asymmetry. To further explore the possible relationship between the severity of hypomimia and the laterality of bradykinesia, another binary logistic regression analysis was performed. No significant relationship was found between laterality of bradykinesia and severity of hypomimia.

In the neuroimaging analysis, a whole series of cortical and GMV maps was obtained. The obtained maps represented the main neuro-anatomical correlates of the whole UPDRS-III scores. Then, to delimit those clusters in association with hypomimia without the collinear contribution of the other UPDRS-III items, LEDD or disease duration, a univariate regression analysis was conducted using hypomimia,
speech and bradykinesia-hypokinesia as independent variables of interest and all the other UPDRS-III scores, age, disease duration and LEDD as covariates. This analysis showed an independent association of hypomimia and lower Cth in the left rostral middle frontal cortex ($r = -0.257; p = 0.004$), in the left superior frontal gyrus ($r = -0.208; p = 0.020$), in the left superior parietal gyrus ($r = -0.250; p = 0.005$), left middle temporal cortex ($r = -0.201; p = 0.025$), the right rostral middle frontal gyrus ($r = -0.212; p = 0.018$) and the right inferior parietal gyrus ($r = -0.210; p = 0.019$). Equivalent associations were found between all these brain regions and the other UPDRS-III items that appeared as contributors to hypomimia such as speech and bradykinesia-hypokinesia. Specifically, a significant association was found between the left ($r = 0.317; p < 0.001$) and right ($r = 0.258; p = 0.004$) rostral middle frontal gyrus thickness and the bradykinesia-hypokinesia score. Regarding the analysis of subcortical GMV, the only region that showed a significant correlation with hypomimia was the posterior portion of the mesencephalon ($r = -0.192; p = 0.028$). The neuroimaging correlates of hypomimia were not significantly altered after controlling for motor laterality (Figure 1).

**DISCUSSION**

The main results of the present study indicate a relationship of hypomimia with few and specific motor and non-motor symptoms of PD. The correlates of hypomimia with other motor symptoms, neuropsychiatric symptoms, cognitive performance as well as neuroimaging data were addressed in a prospective sample of PD patients in the early stages. Although hypomimia represents a very frequent symptom of PD, there are few studies that have explored the clinical and neural correlates of this symptom in a representative sample.

The results highlight different facets that deserve to be considered. First, as anticipated, the severity of hypomimia appeared inseparable from the severity of other motor symptoms. It is to be expected that patients do not present a single motor symptom but a combination of these symptoms whose severity is related. In this sense, collinearity between motor symptoms will always be a common finding. Nevertheless, our results indicate that, regardless of age, disease duration and pharmacological treatment, the severity of hypomimia specifically correlates with a few specific motor items of the UPDRS-III, namely speech and bradykinesia-hypokinesia. This relationship was not considered to be the result of a collinearity effect since it is maintained by controlling for the effect of all the other motor symptoms. In contrast, it is considered that it may reflect the expression of the same cluster of symptoms whose causal mechanisms could be the same. Secondly, no relationship between the severity of hypomimia and the severity of anxiety or cognitive impairment was found. Moreover, the clinical and neuroimaging correlates of hypomimia were not significantly influenced by motor laterality. In contrast, a clear relationship between the severity of hypomimia and the severity of apathy was observed, as well as between the severity of hypomimia and the frequency with which patients express apathy in a clinically significant range. These results do not allow the directionality of this relationship to be clarified. Previous studies have shown a relationship between predominantly rigid-akinetic phenotypes of PD and a higher prevalence of apathy [26, 27]. In this sense, it could be considered that patients with more rigid-akinetic symptomatology and who therefore score higher on bradykinesia-hypokinesia will have not only more severe hypomimia but also more severe apathy.

Another possibility has to do with the effect that apathy itself could have as a modulator of the intensity of facial expression. Apathy in PD is a common and multidimensional symptom characterized by a decrease in goal-oriented behaviors, often accompanied by emotional flattening, loss of initiative and reactivity, and decreased self-activation. As an accompanying feature, several studies have pointed to disturbances of facial expression in patients with apathy, with lack of emotional expression being the most representative feature. Interestingly, facial emotion recognition is also significantly
impaired in PD with isolated apathy compared to non-aphaetic patients [28]. Taken together, these data point to the possible involvement of mechanisms and processes related to the expression and recognition of facial emotions in the genesis of hypomimia and related apathetic symptoms in PD.

From a neuroimaging perspective, with the exception of the middle frontal gyrus at the intersection with the precentral gyrus forming the frontal eye fields (BA 8), the regions that appear most closely related to the severity of hypomimia were not regions that play a central role in motor control. All the other fronto-temporoparietal regions highlighted in the analysis are known to participate both in the recognition and production of facial expressions of emotions [29, 30]. Specifically, the middle and superior frontal cortex, and proximal territories such as the dorsal-lateral prefrontal cortex and the frontal pole, appeared previously associated with the expression and imitation of different types of facial expressions. Similarly, superior parietal and middle temporal regions strongly contribute to decoding and processing facial expressions [29, 30]. In this sense, it would be interesting to explore the role of these structures in the context of hypomimia associated with PD in studies based on dynamic facial expression and recognition processes, and not only in a static context as in the present study.

As limitations of the study, it should be noted that it is a cross-sectional study that does not allow conclusions to be drawn regarding the possible causal relationship between hypomimia and the risk of cognitive impairment. In this sense, longitudinal studies are needed to answer this question. A main limitation of this study is the use of a single-item-based scoring of hypomimia and apathy. Future work using more comprehensive scales should delve into the characterization of their subdomains. Finally, it is evident that some of the associations found at the level of correlation analysis are weak and their replication deserves to be taken into account in future studies.

Taken together, these results confirm that, in addition to being a rigid-akinetic symptom, hypomimia in PD may be partly mediated by the dysfunction of brain systems involved in the recognition, integration and expression of emotions. Consequently, hypomimia in PD may be conceptualized not exclusively as a motor symptom but as a consequence of a multidimensional deficit involving motor-action control deficits and dysfunction of high-order cognitive processes related to the expression and recognition of emotions. Therefore, the mechanisms participating in the development of hypomimia are partially overlapping with those contributing to the expression and recognition of emotion and mood, providing a biologically plausible explanation regarding the association between hypomimia and apathy in PD. Further prospective and longitudinal research should explore whether hypomimia should be taken as an early indicator of apathy in PD.

AUTHOR CONTRIBUTIONS
Frederic Sampedro: Data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal). Sa uuml;l Martinez-Horta: Conceptualization (equal); formal analysis (equal); investigation (equal); methodology (equal); project administration (equal); writing – original draft (equal); writing – review and editing (equal). Andrea Horta-Barba: Data curation (equal); investigation (equal); writing – review and editing (equal). Michel J. Grothe: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Miguel Angel Labrador-Espinosa: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Silvia Jesus: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Astrid Adarmes: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Arnaud Puig-Davi: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Florinda Roldan-Lora: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Miquel Aguilar: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Pau Pastor: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Sonia Escalante: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Berta Solano-Vila: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Anna Cots-Foraster: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Javier Ruiz-Martinez: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Francisco Carrillo: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Isabel Gonz uacute;lez-Aramburu: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Jon Infante-Cebriuero: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Jorge Hernandez-Vara: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Oriol De Fabregues: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Teresa de Deus: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Asuncion Avila: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Juan Carlos Mart uacute;nez Castrillo: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). Helena
CORRELATES OF HYPOMIMIA IN PD

Bejr-kasem: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). **Antonia Campolongo**: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). **Berta Pascual-Sedano**: Investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). **Pablo Martínez-Martín**: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal); writing – review and editing (equal). **Jaime Kulisevsky**: Conceptualization (equal); formal analysis (equal); methodology (equal); project administration (equal); writing – original draft (equal); writing – review and editing (equal). **Pedro J Garcia-Ruiz**: Conceptualization (equal); funding acquisition (equal); investigation (equal); methodology (equal); project administration (equal); resources (equal); supervision (equal); validation (equal); writing – original draft (equal); writing – review and editing (equal). **Pablo Mir**: Conceptualization (equal); data curation (equal); investigation (equal); methodology (equal); project administration (equal); resources (equal); writing – original draft (equal); writing – review and editing (equal).

ACKNOWLEDGEMENTS
All patients and their caregivers who collaborated in this study are thanked. Thanks are gratefully extended to “Fundación Española de Ayuda a la Investigación en Parkinson y otras Enfermedades Neurodegenerativas” (Curemos el Parkinson; www.curemospelaparkinson.org) and to Alpha Bioresearch (www.alphabioresearch.com).

FUNDING INFORMATION
Fundación Curemos el Parkinson (https://curemospelaparkinson.org/).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
The protocol and the statistical analysis plan are available on request. De-identified participant data are not available for legal and ethical reasons.

ETHICAL APPROVAL
All procedures were performed in accordance with the standards of the Ethics Committee at each study site, and in accordance with the 1964 Declaration of Helsinki and its later amendments. For this study, approval was received from the Comité de Ética de la Investigación Clínica de Galicia from Spain (2014/534; 02/DEC/2014). Written informed consent from all participants in this study were obtained before the start of the study. COPPADIS-2015 was classified by the AEMPS (Agencia Española del Medicamento y Productos Sanitarios) as a post-authorization prospective follow-up study with the code COH-PAK-2014-01.

ORCID
**Frederic Sampedro** https://orcid.org/0000-0002-3933-1355
**Saul Martínez-Horta** https://orcid.org/0000-0003-0125-7249
**Andrea Horta-Barba** https://orcid.org/0000-0003-0050-5466
**Arnau Puig-Davi** https://orcid.org/0000-0001-8883-4947
**Asuncion Avila** https://orcid.org/0000-0001-8357-0751
**Juan Carlos Martínez-Castrillo** https://orcid.org/0000-0001-7744-6850
**Helena Bejr-Kasem** https://orcid.org/0000-0001-8828-5976
**Diego Santos-García** https://orcid.org/0000-0002-3126-5111
**Pablo Mir** https://orcid.org/0000-0003-1656-302X
**Pedro J. Garcia-Ruiz** https://orcid.org/0000-0001-6194-672X

REFERENCES


MANAGE-PD
Tool for Making Informed Decisions to Aid Timely Management of Parkinson’s Disease

MANAGE-PD allows you to:

- Identify PD patients inadequately controlled on oral medications
- Determine which patients with PD may be adequately controlled on their current treatment regimen or may require changes to their treatment regimen

Scan the QR code to access to the web

Click here to access to the web

MANAGE-PD is an AbbVie Inc. registered Medical Device. It is a collaborative research and development effort between AbbVie Medical Affairs and Health Economics and Outcomes, the Parkinson’s Foundation and an international panel of Movement Disorder Specialists.

©2022 AbbVie Inc. All rights reserved. The Parkinson's Foundation logo is the sole property of the Parkinson Foundation used with written permission. Any use of the Parkinson's Foundation name or logo without Foundation permission is prohibited. All content in https://www.managempd.com/ is intended only for informational use by healthcare professionals and is not offered as or intended to be medical advice for any particular patient. This information is not intended for patients. Only a healthcare professional exercising independent clinical judgement can make decisions regarding appropriate patient care and treatment options considering the unique characteristics of each patient.

PD: Parkinson’s Disease